Return to study ST001948 main page

MB Sample ID: SA183818

Local Sample ID:B18
Subject ID:SU002026
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Female

Select appropriate tab below to view additional metadata details:


Subject:

Subject ID:SU002026
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Female

Factors:

Local Sample IDMB Sample IDFactor Level IDLevel ValueFactor Name
B18SA183818FL022619HumanSpecies
B18SA183818FL022619GDMCase-Control
B18SA183818FL0226191st TrimesterTime
B18SA183818FL0226192Treatment (1=control, 2=treatment)

Collection:

Collection ID:CO002019
Collection Summary:Blood samples (plasma) were collected from participants with GDM and non-GDM affected pregnancies during 10-16 weeks gestation (GDM for GDM cases and Non-GDM for control cases).
Collection Protocol Filename:La_Frano_Lab_Methods_Doc_v8.pdf
Sample Type:Blood (plasma)

Treatment:

Treatment ID:TR002038
Treatment Summary:This was a secondary analysis using samples from the Healthy Beginnings/Comienzos Saludables Study, a randomized clinical trial (RCT) that is part of the Lifestyle Interventions for Expectant Moms (LIFE-Moms) Consortium (Phelan et al., 2018). This RCT focused on the outcomes of behavior lifestyle change on weight gain during gestation. Samples were acquired from two study sites: California Polytechnic State University, San Luis Obispo, California and Miriam Hospital with Women and Infants Hospital in Providence, Rhode Island. This trial was registered as NCT01545934. Eligibility consisted of being 9-16 weeks gestational age, BMI (in kg/m2) ≥ 25 upon study entry height and weight, English or Spanish speaking, age ≥ 18 years old, and singleton pregnancy. Participants were excluded if glycated hemoglobin ≥ 6.5, reported major health diseases, substance abuse, undergoing treatment for serious psychological disorders, had contradictions to aerobic exercise, or who had repeated no-shows or loss of contact during screening. Participants were randomly assigned to two different intervention methods. Group one received enhanced usual care, which represented the control group. Group two had a multi-component lifestyle intervention, which included diet, exercise, and behavioral change. Data was collected throughout pregnancy, including blood samples, diet assessment, and clinic measured GDM diagnosis. Blood samples were taken between gestational weeks 10-16. Since the multi-component lifestyle intervention showed no statistically significant effect on GDM occurrence (p=0.7) (Phelan et al., 2018), the samples used for this secondary analysis are from both the control and treatment groups. There were a total of 34 GDM cases that were collected from the California (n=13) and Rhode Island (n=21) study sites. Samples for 34 GDM cases were matched to 34 healthy controls prior to metabolomics analysis based on age, study entry body mass index (BMI), ethnicity, study site, and treatment. The two groups did not differ in weight gain from entry to 26 weeks.
Treatment Protocol Filename:La_Frano_Treatment_Protocol_v1.pdf

Sample Preparation:

Sampleprep ID:SP002032
Sampleprep Summary:1. 25 µL of plasma were added to 1.5 mL tubes before the addition of 10 µL of 1 µM internal standard solution, followed by 750 µL chilled methanol. 2. Samples were vortexed 30 seconds prior to being centrifuged at 15,000 x G for 10 min. 3. The supernatant was transferred to 1.5 mL high performance liquid chromatography (HPLC) amber glass vials, dried by centrifugal vacuum evaporation, and reconstituted in 100 µL 3:1 acetonitrile:methanol solution with an internal standard [12-[(cyclohexylamino) carbonyl]amino]-dodecanoic acid (CUDA)] solution. 4.The reconstituted solution was vortexed 30 seconds and placed on ice for 10 minutes. 5. The solution was then centrifuged at 10,000 x G for 3 minutes after being transferred to microfilter tubes. 6. The supernatant was transferred to a HPLC vial to be analyzed using the UPLC-MS.
Sampleprep Protocol Filename:La_Frano_Lab_Methods_Doc_v8.pdf

Combined analysis:

Analysis ID AN003170 AN003171 AN003172
Analysis type MS MS MS
Chromatography type HILIC HILIC Reversed phase
Chromatography system Waters Acquity I-Class Waters Acquity I-Class Waters Acquity I-Class
Column Phenomenex Luna NH2 (150 x 2.1mm,3um) Waters Atlantis HILIC (150 x 2.1mm,3um) Grace Prosphere HP C4 (150 x 3mm,3um)
MS Type ESI ESI ESI
MS instrument type QTRAP QTRAP QTRAP
MS instrument name ABI Sciex 4000 QTrap ABI Sciex 4000 QTrap ABI Sciex 4000 QTrap
Ion Mode NEGATIVE POSITIVE POSITIVE
Units Peak Area Peak Area Peak Area

Chromatography:

Chromatography ID:CH002343
Methods Filename:La_Frano_Lab_Methods_Doc_v8.pdf
Instrument Name:Waters Acquity I-Class
Column Name:Phenomenex Luna NH2 (150 x 2.1mm,3um)
Chromatography Type:HILIC
  
Chromatography ID:CH002344
Methods Filename:La_Frano_Lab_Methods_Doc_v8.pdf
Instrument Name:Waters Acquity I-Class
Column Name:Waters Atlantis HILIC (150 x 2.1mm,3um)
Chromatography Type:HILIC
  
Chromatography ID:CH002345
Methods Filename:La_Frano_Lab_Methods_Doc_v8.pdf
Instrument Name:Waters Acquity I-Class
Column Name:Grace Prosphere HP C4 (150 x 3mm,3um)
Chromatography Type:Reversed phase

MS:

MS ID:MS002948
Analysis ID:AN003170
Instrument Name:ABI Sciex 4000 QTrap
Instrument Type:QTRAP
MS Type:ESI
MS Comments:Please see lab methods file.
Ion Mode:NEGATIVE
Acquisition Parameters File:La_Frano_Lab_Methods_Doc_v8.pdf
Processing Parameters File:La_Frano_Lab_Methods_Doc_v8.pdf
Analysis Protocol File:La_Frano_Lab_Methods_Doc_v8.pdf
  
MS ID:MS002949
Analysis ID:AN003171
Instrument Name:ABI Sciex 4000 QTrap
Instrument Type:QTRAP
MS Type:ESI
MS Comments:Please see lab methods file.
Ion Mode:POSITIVE
Acquisition Parameters File:La_Frano_Lab_Methods_Doc_v8.pdf
Processing Parameters File:La_Frano_Lab_Methods_Doc_v8.pdf
Analysis Protocol File:La_Frano_Lab_Methods_Doc_v8.pdf
  
MS ID:MS002950
Analysis ID:AN003172
Instrument Name:ABI Sciex 4000 QTrap
Instrument Type:QTRAP
MS Type:ESI
MS Comments:Please see lab methods file.
Ion Mode:POSITIVE
Acquisition Parameters File:La_Frano_Lab_Methods_Doc_v8.pdf
Processing Parameters File:La_Frano_Lab_Methods_Doc_v8.pdf
Analysis Protocol File:La_Frano_Lab_Methods_Doc_v8.pdf
  logo